查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1518490

传染性肠炎治疗市场 - 按药物类型、给药途径、药物类型、配销通路- 全球预测

Infectious Enteritis Treatment Market - By Drug Type, Route of Administration, Medication Type, Distribution Channel - Global Forecast
出版日期: | 出版商: Global Market Insights Inc. | 英文 170 Pages | 商品交期: 2-3个工作天内

价格
简介目录

由于该领域持续的研发工作，2024 年至 2032 年间，全球传染性肠炎治疗市场的复合年增长率将达到 5.5%。肠炎的特征是通常由感染引起的肠道炎症，对全球健康构成重大挑战。了解病原体机制、诊断工具和治疗方案的进展正在推动创新。研究人员正在探索专门针对引起肠炎的特定病原体而设计的新型抗生素、益生菌和抗病毒药物。

例如，2021 年 2 月，梅奥诊所的研究人员进行了一项最新研究，旨在调查一大群已确诊的弯曲桿菌感染患者的盛行率、与 PI-IBS 相关的症状类型以及危险因子。 「我们的研究结果表明，五分之一的被诊断出患有弯曲桿菌感染的人可能会出现类似于肠躁症的慢性胃肠道症状，」格罗弗博士解释。

此外，疫苗开发的进步有望针对轮状病毒和诺罗病毒等传染源采取预防措施。肠道感染盛行率的上升及其对公共卫生的影响凸显了有效治疗的迫切性。随着研究不断发现新的见解和治疗策略，传染性肠炎治疗市场有望扩大，为这些使人衰弱的疾病提供更好的结果和更好的管理。

整体感染性肠炎治疗产业规模根据药物类型、给药途径、配销通路和地区进行分类。

抗寄生虫药领域将在2024年至2032年经历严格发展。抗寄生虫药物在有效管理这些病症、缩短病程和改善患者预后方面发挥着至关重要的作用。随着研究的进步和诊断能力的提高，对具有功效、安全性和便利性的创新抗寄生虫药物的需求持续增长。这一趋势强调了开发和提供有效治疗方法的重要性，以满足患有寄生虫引起的传染性肠炎的患者不断变化的需求。

注射剂领域的传染性肠炎治疗市场收入将在2024 年至2032 年实现显着的复合年增长率。疗效。它们对于住院患者或因胃肠道症状而无法耐受口服药物的患者特别有价值。由于製剂技术的进步提高了药物稳定性和生物利用度，传染性肠炎治疗中的注射疗法市场正在扩大。这一趋势反映了医疗保健行业致力于透过针对严重胃肠道感染的可用且有效的治疗方案来改善患者的治疗结果。

欧洲传染性肠炎治疗市场从2024年到2032年将呈现出值得称讚的复合年增长率。随着医疗保健提供者优先考虑早期检测和量身定制的治疗干预措施，市场正在扩大。此外，监管支持和研究措施有助于创新疗法的开发，满足该地区多样化的医疗保健需求。由于肠炎的流行仍然是一个公共卫生问题，整个欧洲对可靠、有效的治疗解决方案的需求持续成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 食源性疾病发生率增加
      • 不断成长的研发活动
      • 提高认识和教育
      • 人口老化加剧
    • 产业陷阱与挑战
      • 抗生素抗药性的出现
      • 复杂而严格的监管要求
  • 成长潜力分析
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略展望矩阵

第 5 章：市场估计与预测：按药物类型，2021 - 2032

  • 主要趋势
  • 抗生素
  • 抗寄生虫药
  • 抗痉挛药
  • 其他药物种类

第 6 章：市场估计与预测：按管理途径，2021 年至 2032 年

  • 主要趋势
  • 口服
  • 可注射

第 7 章：市场估计与预测：按药物类型，2021 - 2032

  • 主要趋势
  • 品牌化
  • 泛型

第 8 章：市场估计与预测：按配销通路划分，2021 - 2032 年

  • 主要趋势
  • 医院药房
  • 零售药局
  • 网路药局

第 9 章：市场估计与预测：按地区划分，2021 - 2032 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿联酋
    • 中东和非洲其他地区

第 10 章：公司简介

  • Abbott Laboratories
  • Almirall SA
  • AstraZeneca PLC
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche Ltd
  • GSK plc
  • Medimetriks Pharmaceuticals Inc.
  • Merck KGaA
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Ltd.
简介目录
Product Code: 9216

Global Infectious Enteritis Treatment Market will witness 5.5% CAGR between 2024 and 2032 due to ongoing research and development efforts in the field. Enteritis, characterized by inflammation of the intestine typically caused by infections, poses significant health challenges globally. Advances in understanding pathogen mechanisms, diagnostic tools, and treatment options are driving innovation. Researchers are exploring novel antibiotics, probiotics, and antiviral agents tailored to combat specific pathogens responsible for enteritis.

For instance, in February 2021, Mayo Clinic researchers conducted a recent study to investigate the prevalence, types of symptoms associated with PI-IBS, and risk factors in a large cohort of patients with confirmed campylobacter infection. "Our findings indicated that 1 in 5 individuals diagnosed with campylobacter infection may develop chronic GI symptoms resembling irritable bowel syndrome," explained Dr. Grover.

Moreover, advancements in vaccine development hold promise for preventive measures against infectious agents like rotavirus and norovirus. The rising prevalence of enteric infections and their impact on public health underscore the urgency for effective treatments. As research continues to uncover new insights and therapeutic strategies, the Infectious Enteritis Treatment Market is poised to expand, offering improved outcomes and better management of these debilitating conditions.

The overall infectious enteritis treatment Industry size is classified based on the drug type, route of administration, distribution channel, and region.

The antiparasitics segment will undergo rigorous development from 2024 to 2032. Enteritis caused by parasites such as Giardia and Cryptosporidium requires targeted treatments to alleviate symptoms and eradicate infections. Antiparasitic drugs play a crucial role in effectively managing these conditions, reducing disease duration, and improving patient outcomes. As research advances and diagnostic capabilities improve, the demand for innovative antiparasitics that offer efficacy, safety, and convenience continues to grow. This trend underscores the importance of developing and delivering effective treatments to meet the evolving needs of patients suffering from infectious enteritis caused by parasitic organisms.

The infectious enteritis treatment market revenue from the injectable segment will register a notable CAGR from 2024 to 2032. Injectable treatments play a pivotal role in managing severe cases of enteritis caused by bacterial or viral infections, providing rapid delivery and efficacy. They are particularly valuable in hospitalized patients or those unable to tolerate oral medications due to gastrointestinal symptoms. The market for injectable therapies in infectious enteritis treatment is expanding due to advancements in formulation technology, which enhance drug stability and bioavailability. This trend reflects the healthcare industry's commitment to improving patient outcomes through accessible and effective treatment options for serious gastrointestinal infections.

Europe infectious enteritis treatment market will showcase a commendable CAGR from 2024 to 2032. European countries are investing in advanced diagnostic tools and effective treatment options to combat enteritis caused by various pathogens. The market is expanding as healthcare providers prioritize early detection and tailored therapeutic interventions. Additionally, regulatory support and research initiatives contribute to the development of innovative treatments, meeting the region's diverse healthcare needs. As the prevalence of enteritis remains a public health concern, the demand for reliable and efficient treatment solutions continues to rise across Europe.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing incidence of foodborne disease
      • 3.2.1.2 Growing R&D activities
      • 3.2.1.3 Increasing awareness and education
      • 3.2.1.4 Growing ageing population
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Emergence of antibiotic resistance
      • 3.2.2.2 Complex and stringent regulatory requirements
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Antibiotics
  • 5.3 Antiparasitics
  • 5.4 Anti-spasmodics
  • 5.5 Other drug types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Oral
  • 6.3 Injectable

Chapter 7 Market Estimates and Forecast, By Medication Type, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Branded
  • 7.3 Generics

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies
  • 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 South Africa
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Abbott Laboratories
  • 10.2 Almirall SA
  • 10.3 AstraZeneca PLC
  • 10.4 Bristol-Myers Squibb
  • 10.5 F. Hoffmann-La Roche Ltd
  • 10.6 GSK plc
  • 10.7 Medimetriks Pharmaceuticals Inc.
  • 10.8 Merck KGaA
  • 10.9 Pfizer Inc.
  • 10.10 Teva Pharmaceutical Industries Ltd.
  • 10.11 Zydus Lifesciences Ltd.